RSVP for a One-on-One Meeting and Product Samples
(Limited inventory, First come-first served)
Experience first-hand the effective ultrasound tubal patency assessment using ExEm^® Foam and the HyFoSy Procedure at the ARM/NPG Meeting in Denver, Colorado, from May 5 – 6, 2023. Our DNP/Clinical Lead will teach you the quick and easy steps to constitute ExEm^® Foam, optimal scanning techniques and how to make an assessment, with the distinct and highly echogenic images produced by the ExEm^® Foam contrast media.

Visit our booth to learn more:

• Patient-friendly benefits and effectiveness of ExEm^® Foam/HyFoSy
• In-clinic HyFoSy training opportunities
• HyFoSy ultrasound imaging samples
• New programs to benefit your clinic(s) and patients
• Product samples

RSVP for a one-on-one demo and meet with a team member for information on:

• In-clinic HyFoSy training opportunities
• HyFoSy ultrasound imaging samples
• New programs to benefit your clinic(s) and patients
• Product samples

About the Association for Reproductive Managers (ARM)
The Association of Reproductive Managers (ARM), a Professional Group of the American Society for Reproductive Medicine (ASRM), is committed to advancing the art and science of fertility practice management through leadership, research, and education. ARM’s mission is to create a forum through which fertility program business managers and physicians can form nationwide interrelationships to keep abreast of critical fertility practice management issues; to provide educational programs designed to help advanced assisted reproductive technology (ART) programs improve the operations of their practices from both internal and external standpoints including planning, marketing, and financial functions; to solve management problems including the identification and correction of deficiencies; and to provide guidelines for enhancement of the organization’s capabilities.

About the Nurses’ Professional Group (NPG)
The Nurses’ Professional Group (NPG) is composed of nurse members of the American Society for Reproductive Medicine (ASRM). Its purpose is to foster the Society’s goals within the practice of professional nursing. They are committed to improving patient care and providing a forum for networking and exchanging information among nurses.

To learn more about ARM & NPG Joint Meeting, visit: ARM and NPG 2023 Joint Meeting – ARM (asrm.org)

IMPORTANT SAFETY INFORMATION
ExEm^® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.

Click here for full prescribing information.

‍About ExEm^® Foam Inc
ExEm^® Foam Inc. is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm^® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm^® Foam has been used in more than 1,000,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm^® Foam Inc. is headquartered in Nashville, TN.

For more information, please visit www.exemfoam.com.